Funded Biotechnology Startups in United States
Among the 15 most recent disclosed biotechnology/healthcare rounds shown, the largest disclosed amount is Expedition Therapeutics’ $165M (Series A) on 2025…
Among the 15 most recent disclosed biotechnology/healthcare rounds shown, the largest disclosed amount is Expedition Therapeutics’ $165M (Series A) on 2025-10-09, which dwarfs the rest of the disclosed figures in this slice. The next-highest disclosed amounts are $101M (NILO Therapeutics, Series A, 2025-10-08) and $23M (Predicta Biosciences, Series A, 2025-10-01), with several smaller rounds in the sub-$5M range.
The rounds cluster tightly in late 2025: the list spans 2025-09-24 through 2025-11-16, and many entries fall in mid-October (for example, $165M on 2025-10-09 and $101M on 2025-10-08). Stage reporting is mixed: 5 of the 15 rows are marked “Series Unknown” (Azure Biosystems and Leukogene Therapeutics on 2025-11-10; BlueWhale Bio on 2025-10-19; Oral Biolife on 2025-10-17; plus Real Diagnostics, 2025-09-24), and 3 rows are explicitly “undisclosed” by amount (Azure Biosystems 2025-11-10; Leukogene Therapeutics 2025-11-10; Oral Biolife 2025-10-17; Real Diagnostics 2025-09-24).
Most recent rounds
15 shownRelated listings
Frequently asked
What stands out as the largest disclosed biotech round here, and how far ahead is it of the rest?
Expedition Therapeutics’ $165M (Series A) on 2025-10-09 is the largest disclosed amount in the 15-row view, and it sits far above the next-highest disclosed figures: NILO Therapeutics’ $101M on 2025-10-08 and Predicta Biosciences’ $23M on 2025-10-01.
Is there a tight timing cluster in these recent rounds, or are they spread out?
They’re concentrated toward late Q3 to mid-November 2025, spanning 2025-09-24 (Real Diagnostics, Private Equity) through 2025-11-16 (Rion Vet, Series A). Several of the biggest disclosed rounds land within a one-day window in October: $165M on 2025-10-09 and $101M on 2025-10-08.
How often do stage labels come through as “Series Unknown” versus disclosed named stages?
Named stages appear alongside multiple “Series Unknown” entries: 5 of 15 rows are labeled “Venture - Series Unknown” (Azure Biosystems and Leukogene Therapeutics on 2025-11-10; BlueWhale Bio on 2025-10-19; Oral Biolife on 2025-10-17; and Real Diagnostics on 2025-09-24). Disclosed named rounds include multiple Seeds (Modulight Bio on 2025-11-12; Gut Brain Axis Therapeutics and iOrganBio in early/mid November; AccufyDx on 2025-09-30) and several Series A rounds (Rion Vet, Expedition Therapeutics, NILO Therapeutics, Predicta Biosciences).
Are any disclosed amounts clearly outliers on the low end?
Yes. The smallest disclosed amount shown is $200K for AccufyDx on 2025-09-30 (Seed), which is well below the other disclosed sub-$1M/low-mid amounts like Gregor Diagnostics’ $240K on 2025-11-09, and far below the $2M-to-$12M band seen for entries such as Gut Brain Axis Therapeutics ($2M on 2025-11-06) and Modulight Bio ($12M on 2025-11-12).
Which cities appear to recur, and do they suggest any geographic clustering in this slice?
Within this 15-row view, geography looks more like broad distribution than a single hub: Boston appears twice (Modulight Bio in Boston, 2025-11-12, and Predicta Biosciences in Boston, 2025-10-01). Beyond that, most cities are singletons (for example, Rochester for Rion Vet; San Francisco for Expedition Therapeutics; New York for NILO Therapeutics; Philadelphia for BlueWhale Bio).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.